Cost-effectiveness of primary prevention of type 2 diabetes

被引：0
|
作者：
Icks, A. [1 ,2 ]
Chernyak, N. [1 ,2 ]
Klein, A. [1 ]
Brinks, R. [1 ]
Genz, J. [1 ]
Giani, G. [1 ]
机构：
[1] Deutsch Diabet Zentrum, Inst Biometrie & Epidemiol, Arbeitsgrp Versorgungsforsch & Gesundheitsokon, D-40225 Dusseldorf, Germany
[2] Univ Dusseldorf, Fak Med, Ctr Hlth & Soc, Funkt Bereich Publ Hlth, Dusseldorf, Germany
来源：
DIABETOLOGE | 2011年 / 7卷 / 02期
关键词：
Diabetes prevention; Lifestyle intervention; Pharmacological intervention; Health economic evaluation; LIFE-STYLE INTERVENTION; IMPAIRED GLUCOSE-TOLERANCE; FOLLOW-UP; REDUCTION; METFORMIN; ACARBOSE; PROGRAM;
D O I：
10.1007/s11428-010-0638-z
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Type 2 diabetes mellitus (T2DM) represents a large burden for patients and society and its prevalence is increasing worldwide. There is evidence that T2DM can be delayed or prevented by interventions such as pharmacological and lifestyle interventions in individuals with pre-diabetes. However, the question emerges whether the implementation of these interventions is cost-effective. This article presents studies concerning the cost-effectiveness of interventions targeting primary prevention of T2DM which have been identified in a systematic review of the literature. In all 11 identified studies primary prevention of T2DM was shown to be potentially cost-effective.
引用
收藏
页码：92 / 98
页数：7
相关论文
共 50 条
  • [1] Cost-effectiveness of primary prevention of type 2 diabetes. A systematic review
    Klein, A.
    Chernyak, N.
    Brinks, R.
    Genz, J.
    Icks, A.
    [J]. PRAVENTION UND GESUNDHEITSFORDERUNG, 2011, 6 (02): : 102 - 110
  • [2] Cost-Effectiveness of Primary Prevention of Type 2 Diabetes: An Update of Systemetic Review
    Li, Rui
    Zhang, Ping
    [J]. DIABETES, 2013, 62 : A325 - A325
  • [3] Cost-Effectiveness of Primary Prevention with Statin Treatment for Chinese Patients with Type 2 Diabetes
    Li, Te
    Wan, Xu
    Ma, Jin
    Wu, Bin
    [J]. ADVANCES IN THERAPY, 2018, 35 (12) : 2214 - 2223
  • [4] Cost-Effectiveness of Primary Prevention with Statin Treatment for Chinese Patients with Type 2 Diabetes
    Te Li
    Xu Wan
    Jin Ma
    Bin Wu
    [J]. Advances in Therapy, 2018, 35 : 2214 - 2223
  • [5] Cost-effectiveness issues in type 2 diabetes prevention in the USA
    Palmer, AJ
    Roze, S
    [J]. DIABETES, 2002, 51 : A279 - A279
  • [6] COST-EFFECTIVENESS OF STATINS FOR PRIMARY PREVENTION IN NEWLY DIAGNOSED TYPE 2 DIABETES PATIENTS IN THE NETHERLANDS
    de Vries, F. M.
    Denig, P.
    Visser, S. T.
    Hak, E.
    Postma, M. J.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A526 - A526
  • [7] Cost-Effectiveness of Statins for Primary Prevention in Patients Newly Diagnosed with Type 2 Diabetes in The Netherlands
    de Vries, Folgerdiena M.
    Denig, Petra
    Visser, Sipke T.
    Hak, Eelko
    Postma, Maarten J.
    [J]. VALUE IN HEALTH, 2014, 17 (02) : 223 - 230
  • [8] Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes
    [J]. DIABETES CARE, 2003, 26 (09) : 2518 - 2523
  • [9] Cost-Effectiveness of Statins for Primary Prevention in Newly Diagnosed Type 2 Diabetes Patients: An Illustration for the Netherlands
    de Vries, Folgerdiena M.
    Denig, Petra
    Visser, Sipke T.
    Hak, Eelko
    Postma, Maarten J.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 117 - 118
  • [10] A systematic review of the cost-effectiveness of lifestyle modification as primary prevention intervention for diabetes mellitus type 2
    Radl, Katrin I.
    Ianuale, Carolina
    Boccia, Stefania
    [J]. EPIDEMIOLOGY BIOSTATISTICS AND PUBLIC HEALTH, 2013, 10 (02)
12345